Peptide blend protocol

Wolverine Stack (20 mg)

Wolverine Stack 20mg dosage protocol. BPC-157 + TB-500 reconstitution, injection schedule, and syringe measurements.

Peptides
bpc-157 + tb-500
Vial
20 mg
Water
2 mL
Concentration
10.00 mg/mL
Wolverine Stack (20 mg)

At a Glance

The Wolverine Stack is a pre-mixed 20 mg vial containing BPC-157 (10 mg) + TB-500 (10 mg) in a 1:1 ratio — the most widely used research peptide combination for musculoskeletal recovery. BPC-157 drives local repair; TB-500 provides systemic healing support. Together they address all three phases of tissue healing.[1][2]

  • Reconstitute: Add 2.0 mL bacteriostatic water → 10.0 mg/mL total blend (5.0 mg/mL each component).
  • Loading dose: 500 mcg total (5 units / 0.05 mL) once daily for 4 weeks.
  • Easy measuring: At 10.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 100 mcg total blend.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

  • Composition: BPC-157 10 mg + TB-500 10 mg (1:1 ratio) in a pre-mixed 20 mg lyophilised vial.
  • Goal: Comprehensive musculoskeletal tissue repair combining BPC-157's local healing with TB-500's systemic reach.[1][2]
  • Schedule: Daily SC injection for 4-week loading, then 3× weekly maintenance.
  • Reconstitution: 2.0 mL BAC water per 20 mg vial → 10.0 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on a 4-week loading cycle at 500 mcg once daily (28 injections, 14 mg total blend).

  • Wolverine Stack Vials (20 mg each): 14 mg ÷ 20 mg per vial → 1 vial covers the full 28-day loading cycle.
  • Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 28 injections → 28 syringes.
  • Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle per vial.
  • Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.

How to Reconstitute

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; avoid injecting directly onto the powder cake.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date and both peptide names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

WeekTotal Blend DoseUnits (U-100)VolumeFrequency
Loading (Weeks 1–4)500 mcg5 units0.05 mLOnce daily
Maintenance (Weeks 5+)500 mcg5 units0.05 mL3× weekly

Each daily 500 mcg dose delivers approximately 250 mcg BPC-157 + 250 mcg TB-500. At 500 mcg/day the 20 mg vial (2.0 mL reconstituted) provides 40 daily doses — enough for a full 28-day loading cycle with 12 days to spare, or exactly 40 doses for a 6-week loading period at 5 days/week. Transition to the 3× weekly maintenance schedule once initial healing goals are met.

Protocol Details

  • Loading (Weeks 1–4): 500 mcg (5 units / 0.05 mL) once daily SC → ~250 mcg BPC-157 + ~250 mcg TB-500.[1]
  • Maintenance (Weeks 5+): 500 mcg (5 units / 0.05 mL) three times weekly SC.
  • Injection site: Near injury site for BPC-157's local effect; abdomen or thigh adequate for TB-500's systemic distribution.
  • Duration: Assess at week 8; extend loading or continue maintenance based on healing progress.

Storage

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy or particulate.

How the Wolverine Stack Works

BPC-157 and TB-500 address tissue healing through complementary, non-overlapping mechanisms that together cover all three phases of tissue repair:

  • Phase 1 — Inflammatory (Days 1–5): TB-500 down-regulates NF-κB and pro-inflammatory cytokines (IL-6, TNF-α); BPC-157 normalises the NO pathway and reduces prostaglandin E2 — together shortening the inflammatory phase.[2]
  • Phase 2 — Proliferative (Days 5–21): BPC-157 activates FAK-paxillin in tendon fibroblasts and endothelial cells; TB-500 enables cell migration via G-actin sequestration. Both drive angiogenesis to restore blood supply to the injured site.[1]
  • Phase 3 — Remodelling (Weeks 3+): TB-500 reduces myofibroblast persistence, limiting fibrosis; BPC-157 supports collagen organisation and tendon cell maturation for restoration of mechanical strength.

Good to Know

  • The pre-mixed vial ensures consistent 1:1 dosing of both components — no need for individual reconstitution and mixing.
  • For acute localised injuries, inject subcutaneously within 2–5 cm of the injury site to maximise BPC-157's local FAK-paxillin effects.
  • WADA-prohibited — both BPC-157 and TB-500 are classified as non-approved peptide hormones (Category S2). Athletes subject to anti-doping rules must not use this stack.
  • Track pain scores (NRS scale), range of motion, and swelling at weeks 2, 4, and 8.
  • The Wolverine Stack can be upgraded to the GLOW or KLOW blend for broader tissue repair and skin/immune support. See KLOW Protocol.
  • Musculoskeletal repair: BPC-157 orthopaedic review: 35 preclinical studies + 1 human pilot showing benefit in tendon, muscle, bone, and cartilage repair.[1]
  • Systemic reach: TB-500 distributes body-wide after SC injection, supporting healing in multiple tissues simultaneously.[2]
  • Gut protection: BPC-157 component provides additional gut mucosal protection — useful for athletes using NSAIDs during recovery.
  • Complementary mechanisms: Local (BPC-157) + systemic (TB-500) repair is more comprehensive than either peptide alone.
  • WADA status: Both components prohibited in- and out-of-competition. Not suitable for tested athletes.
  • For background on the Wolverine Stack's mechanism, evidence, and safety profile, see What Is the Wolverine Stack?.

Tips for Best Results

  • Maintain adequate dietary protein (1.2–1.6 g/kg body weight) for tissue synthesis.
  • Gentle range-of-motion exercises within pain-free range support capillary ingrowth and fibroblast recruitment.
  • Avoid NSAIDs — they blunt prostaglandin-mediated repair signalling that BPC-157 potentiates.
  • Adequate sleep (7–9 hours) maximises overnight tissue repair processes.

Injection Tips

  • Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
  • Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
  • Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.

Related on pep-dose

Sources

  1. Gwyer D et al. — PMC (2025) — BPC-157 Orthopaedic Review
  2. Goldstein AL & Kleinman HK — Annals of the New York Academy of Sciences (2015)
  3. Bachem Peptide Technical Guide
  4. CDC — General Best Practice Guidelines for Immunization